First-World Type 2 Drug Market to Reach $47 Billion by 2022


By: Diabetes Health Staff

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.

The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase in the type 2 patient population and the introduction of new drugs.

The report says that proprietary DPP-4 inhibitors, such as Merck’s Januvia (sitagliptin), will continue lead the market in terms of overall share through 2022. However, Decision Resources predicts that sales in the DPP-4 inhibitor category will peak at $14 billion by 2021 then erode in the wake of the introduction of generic versions.

A newer drug category, the SGLT-2 inhibitors, which work by expelling glucose through the kidneys, are predicted to be the fastest growing class of type 2 drugs. Examples of the class include Invokana from Johnson & Johnson, and Forxiga from AstraZeneca/Bristol-Myers.

Another contributor to drug sales growth will be from attempts by pharmaceutical companies to distinguish their products by combining current therapies into novel combinations, such as long-acting insulin and GLP-1 receptor agonist (such as Byetta and Victoza).



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.